Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
Seminars in Urologic Oncology|December 19, 2002
Chemotherapy for good-risk germ-cell tumorsCharles J Ryan, Dean F Bajorin
Clinical Genitourinary Cancer|October 10, 2009
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903)Dean F Bajorin, Susan Halabi, Eric Small
Expert Review of Anticancer Therapy|November 30, 2010
Novel strategies for treating relapsed/refractory urothelial carcinomaGopa Iyer, Matthew I Milowsky, Dean F Bajorin
Nature Reviews. Urology|April 13, 2010
False elevation of human chorionic gonadotropin in a patient with testicular cancerDavid J Gallagher, Jamie Riches, Dean F Bajorin
Hematology/Oncology Clinics of North America|April 4, 2015
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patientsWassim Abida, Dean F Bajorin, Jonathan E Rosenberg
Therapeutic Advances in Urology|September 10, 2011
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomyArjun Balar, Dean F Bajorin, Matthew I Milowsky
Future Oncology (London, England)|October 2, 2009
Clinical states model for biomarkers in bladder cancerAndrea B Apolo, Matthew Milowsky, Dean F Bajorin
Cancer|July 17, 2008
Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line settingDavid J Gallagher, Matthew I Milowsky, Dean F Bajorin
BJU International|November 28, 2008
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancerMatthew I Milowsky, Walter M Stadler, Dean F Bajorin
The Journal of Urology|January 16, 2007
Defining optimal therapy for muscle invasive bladder cancerHarry W Herr, Zohar Dotan, S Machele Donat, et al.
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
Seminars in Urologic Oncology|December 19, 2002
Chemotherapy for good-risk germ-cell tumorsCharles J Ryan, Dean F Bajorin
Clinical Genitourinary Cancer|October 10, 2009
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903)Dean F Bajorin, Susan Halabi, Eric Small
Expert Review of Anticancer Therapy|November 30, 2010
Novel strategies for treating relapsed/refractory urothelial carcinomaGopa Iyer, Matthew I Milowsky, Dean F Bajorin
Nature Reviews. Urology|April 13, 2010
False elevation of human chorionic gonadotropin in a patient with testicular cancerDavid J Gallagher, Jamie Riches, Dean F Bajorin
Hematology/Oncology Clinics of North America|April 4, 2015
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patientsWassim Abida, Dean F Bajorin, Jonathan E Rosenberg
Therapeutic Advances in Urology|September 10, 2011
Management of invasive bladder cancer in patients who are not candidates for or decline cystectomyArjun Balar, Dean F Bajorin, Matthew I Milowsky
Future Oncology (London, England)|October 2, 2009
Clinical states model for biomarkers in bladder cancerAndrea B Apolo, Matthew Milowsky, Dean F Bajorin
Cancer|July 17, 2008
Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line settingDavid J Gallagher, Matthew I Milowsky, Dean F Bajorin
BJU International|November 28, 2008
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancerMatthew I Milowsky, Walter M Stadler, Dean F Bajorin
The Journal of Urology|January 16, 2007
Defining optimal therapy for muscle invasive bladder cancerHarry W Herr, Zohar Dotan, S Machele Donat, et al.
Pageof 17